sector · cluster
Aging & longevity
Treat aging as the disease that drives every other disease.
Most chronic disease — cancer, cardiovascular, Alzheimer's — has aging as its dominant risk factor. Targeting aging upstream (senolytics, rapamycin analogues, partial reprogramming, NAD+ restoration) compounds across every downstream condition. The frontier is regulatory as much as scientific: FDA does not yet treat 'aging' as an indication.
Problems in this sector
1 rankedCompanies on it
8 mapped →De-extinction and genetic engineering. Biosecurity adjacency via rapid genome editing and cold-chain logistics.
AI-driven drug discovery. Industrializes biology through automated phenotypic screening at scale.
Alphabet-spinoff applying AlphaFold-class ML to drug design. Deals with Novartis and Eli Lilly.
Cellular rejuvenation via partial reprogramming. $3B at founding with Shinya Yamanaka on scientific board.
Alphabet company for aging biology. Research partnership with AbbVie; long-horizon mandate rare in pharma.
Cellular reprogramming, autophagy, and plasma-exchange therapeutics. Seed-funded by Sam Altman at $180M.
Partial reprogramming for aging, started by Blake Byers, Jacob Kimmel, and Brian Armstrong.
FDA-track longevity drug for dogs. First-of-its-kind lifespan-extension regulatory pathway.
Capital on it
5 allocators →Emergent Ventures
GrantFast grants. High-variance, unconventional, talent-first.
Thiel Fellowship
Fellowship$100k to stop out of school and build something important.
Deep Science Ventures
Venture StudioOutcome-first venture creation. Define the holy-grail outcome, then recruit founders.
Founders Fund
Venture CapitalContrarian hard tech that rebuilds the industrial base.
Lux Capital
Venture CapitalCounter-conventional science at the edges of physics and biology.